High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements

High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements — Trials · CancerIndex

Clinical trials

Registered studies

44 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 30
Recruiting: 17
Ph III recruiting: 0
Growth YoY: —
Industry share: 10%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (4)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03103971	huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia	terminated	Phase 1	55	Fred Hutchinson Cancer CenterOTHER	1	Apr 10, 2024	clinicaltrials
NCT02706405	JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	terminated	Phase 1	30	Fred Hutchinson Cancer CenterOTHER	1	Aug 24, 2022	clinicaltrials